Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
Zevra Therapeutics (NASDAQ: ZVRA), a commercial-stage company focused on rare disease therapies, has scheduled its Q1 2025 financial results announcement for Tuesday, May 13, 2025. The company will release its corporate and financial results after market close, followed by a conference call and audio webcast at 4:30 p.m. ET.
Investors can access the webcast through Zevra's website investor relations section. For telephone participation, U.S. callers can dial (800) 245-3047, while international participants should use +1 (203) 518-9765, with Conference ID: ZVRAQ125. A replay will be available on the company's website for 90 days following the presentation.
Zevra Therapeutics (NASDAQ: ZVRA), un'azienda in fase commerciale specializzata in terapie per malattie rare, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per martedì 13 maggio 2025. La società pubblicherà i risultati aziendali e finanziari dopo la chiusura del mercato, seguiti da una conference call e una trasmissione audio in webcast alle 16:30 ET.
Gli investitori potranno accedere al webcast tramite la sezione relazioni con gli investitori del sito web di Zevra. Per partecipare telefonicamente, i chiamanti dagli Stati Uniti possono comporre il numero (800) 245-3047, mentre i partecipanti internazionali dovranno utilizzare +1 (203) 518-9765, con ID conferenza: ZVRAQ125. Una registrazione sarà disponibile sul sito della società per 90 giorni dopo la presentazione.
Zevra Therapeutics (NASDAQ: ZVRA), una empresa en etapa comercial enfocada en terapias para enfermedades raras, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el martes 13 de mayo de 2025. La compañía publicará sus resultados corporativos y financieros después del cierre del mercado, seguido de una llamada en conferencia y una transmisión por audio webcast a las 4:30 p.m. ET.
Los inversores pueden acceder al webcast a través de la sección de relaciones con inversores en el sitio web de Zevra. Para participar por teléfono, los llamantes desde EE. UU. pueden marcar (800) 245-3047, mientras que los participantes internacionales deben usar +1 (203) 518-9765, con ID de conferencia: ZVRAQ125. Una repetición estará disponible en el sitio web de la compañía durante 90 días después de la presentación.
Zevra Therapeutics (NASDAQ: ZVRA)는 희귀 질환 치료제에 중점을 둔 상업 단계 기업으로, 2025년 1분기 재무 실적 발표를 2025년 5월 13일 화요일로 예정했습니다. 회사는 시장 마감 후 기업 및 재무 실적을 발표하며, 이어서 동부 표준시 오후 4시 30분에 컨퍼런스 콜과 오디오 웹캐스트를 진행합니다.
투자자들은 Zevra 웹사이트의 투자자 관계 섹션을 통해 웹캐스트에 접속할 수 있습니다. 전화 참여를 원할 경우, 미국 내 발신자는 (800) 245-3047로 전화하고, 국제 참가자는 +1 (203) 518-9765를 사용하며, 회의 ID는 ZVRAQ125입니다. 발표 후 90일 동안 회사 웹사이트에서 다시보기 서비스를 이용할 수 있습니다.
Zevra Therapeutics (NASDAQ : ZVRA), une entreprise en phase commerciale spécialisée dans les thérapies pour les maladies rares, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le mardi 13 mai 2025. La société publiera ses résultats corporatifs et financiers après la clôture du marché, suivis d'une conférence téléphonique et d'une diffusion audio en webcast à 16h30 ET.
Les investisseurs peuvent accéder au webcast via la section relations investisseurs du site web de Zevra. Pour participer par téléphone, les appelants américains peuvent composer le (800) 245-3047, tandis que les participants internationaux doivent utiliser le +1 (203) 518-9765, avec l'ID de conférence : ZVRAQ125. Une rediffusion sera disponible sur le site de la société pendant 90 jours après la présentation.
Zevra Therapeutics (NASDAQ: ZVRA), ein Unternehmen in der kommerziellen Phase mit Schwerpunkt auf Therapien für seltene Krankheiten, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 13. Mai 2025 geplant. Das Unternehmen wird seine Unternehmens- und Finanzergebnisse nach Börsenschluss veröffentlichen, gefolgt von einer Telefonkonferenz und einem Audio-Webcast um 16:30 Uhr ET.
Investoren können über den Bereich Investor Relations auf der Website von Zevra auf den Webcast zugreifen. Für die telefonische Teilnahme können Anrufer aus den USA die Nummer (800) 245-3047 wählen, internationale Teilnehmer nutzen +1 (203) 518-9765 mit der Konferenz-ID: ZVRAQ125. Eine Aufzeichnung wird für 90 Tage nach der Präsentation auf der Website des Unternehmens verfügbar sein.
- None.
- None.
Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025
CELEBRATION, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the first quarter 2025 on Tuesday, May 13, 2025. The Company will issue a news release after the market closes and host a conference call/audio webcast at 4:30 p.m. ET that day.
A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at https://investors.zevra.com/.
To join via telephone, please use the following dial-in information:
- (800) 245-3047 (United States)
- +1 (203) 518-9765 (International)
- Conference ID: ZVRAQ125
A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the “Events & Presentations” page of Zevra’s website at https://investors.zevra.com/.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient need to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended Dec. 31, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
FAQ
When will Zevra Therapeutics (ZVRA) report Q1 2025 earnings?
How can I listen to Zevra Therapeutics' (ZVRA) Q1 2025 earnings call?
How long will Zevra Therapeutics' (ZVRA) Q1 2025 earnings call replay be available?
What is Zevra Therapeutics' (ZVRA) main business focus?
